Skip to main content

The Globe and Mail

Valeant Pharma insiders still buy the growth story

Shares of Valeant are up 130 per cent since November 26, 2011.


Shares of Valeant Pharmaceuticals International Inc. are up 130 per cent since we reported on insider buying on November 26, 2011. While it would be unusual to see the past rate of share price gains persist, insiders appear confident the growth story will continue. Over the past 30 days, insiders have been net buyers of 61,532 shares through the public market. One of the recent purchasers was director Ron Farmer, who picked 2,500 shares between the prices $99.99 (U.S.) and $103.90. The stock trades in both Toronto and New York.

Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.

Infographic reflects public-market transactions of common shares or unit trusts by company officers and directors.

Story continues below advertisement

Report an error

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨